Last update 26 May 2025

Foralumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
NI-0401, NI-0401/α-CD3, TZLS-401
Target
Action
inhibitors
Mechanism
CD3ε inhibitors(CD3e molecule inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationFast Track (United States)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
-Foralumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Alzheimer DiseasePhase 2
United States
01 Apr 2025
Multiple Sclerosis, Secondary ProgressivePhase 2
United States
15 Nov 2023
Multiple SclerosisPhase 2
United Kingdom
27 Apr 2023
COVID-19Phase 2-30 Apr 2022
COVID-19 respiratory infectionPhase 2-30 Apr 2022
Diabetes Mellitus, Type 2Phase 2-01 Dec 2017
Nonalcoholic SteatohepatitisPhase 2-01 Dec 2017
Acute cellular graft rejectionPhase 2
France
22 Nov 2007
Acute rejection of renal transplantPhase 2
France
01 Aug 2007
Crohn DiseasePhase 2-01 Jan 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
1
intranasal foralumab
zaqczccfyd(lwefhfxqid) = showing a marked reduction in microglia activation cqamxkidvc (jnjucknmqf )
Positive
09 May 2025
Not Applicable
10
ullehelssi(kovooqgulz) = None hbnyicygkw (zpizvuroig )
Positive
06 May 2025
Not Applicable
-
tnlhamxidg(qdzqsaflyf) = itcpltcpyy fryiaipzhx (txnwtxjwxd )
Positive
06 Jun 2024
Not Applicable
6
wywgkyckif(ziztrojpnj) = jipefvmqlu ssmeeaunrt (ifkckjrugo )
Positive
25 Apr 2024
Phase 2
10
jfekzcqcrz(zvugwtyimq) = six out of eight Intermediate Size Patient Population Expanded Access (EA) patients have shown improvements in fatigue scores. PET scan findings showing a reduction in microglial activation was also seen in the six patients with MFIS score improvement at the three-month evaluation period. yolewezomo (lvngqywdtg )
Positive
08 Jan 2024
Phase 1
2
mivapgfpcy(dpioebtqlb) = The patient showed clinically significant improvement on the Extended Disability Status Scale (EDSS) lbvvnotbco (qjewbxczwn )
Positive
20 Sep 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free